S1p-receptor-agonist-1

Research use only, not for human use.

An S1P receptor agonist.

S1p receptor agonist 1 is an S1P receptor agonist extracted from patent WO 2015039587 A1, compound example 2. Sphingosine 1-phosphate (S1P) suppresses the collagen-induced activation of human platelets via S1P4 receptor. S1P inhibits the collagen-induced human platelet activation through S1PR4 but not S1PR1.

——

Icanbelimod (oral administration; 0.01 mg/kg-1 mg/kg) at all dose is active, and only a dose of 0.01 mg/kg is required to observe a decrease in the number of peripheral blood lymphocytes by more than 50% and a decrease in the 1 mg/kg dose. Besides, this compound islymphocyte-specific, which dose not significantly alter the number of peripheral monocytes and other white blood cells in SD rats.Icanbelimod (oral administration; 3 mg/kg; 12 days)is has been proved to block lymphocyte efflux. In the development of type II collagen-induced arthritis in rat model, compound 2 is effective in inhibiting the development of joint swelling in arthritis andjoint structure destruction.Icanbelimod (oral administration; 0.3-1mg/kg; 30 days; once daily) inhibits the development of experimental autoimmune encephalitis (EAE) as a dose-dependent manner in mice model. Animal Model:Lewis ratsDosage:3 mg/kgAdministration:Oral administrationResult:Decreased the severity score of arthritis in the four-legged rats.Animal Model:Female C57BL/6 mice?Dosage:0.03, 0.1, and 1 mg/kg Administration:Oral administration Result:Decreased the severity score of EAE in MOG 35-55?induced mice.

S1P-agonist-1 | DC10392 | S1p receptor agonist 1

Others

Other Targets

S1P

——

——

1514888-56-2

409.45

C23H24FN3O3

>98% (HPLC)

DMSO : 6.8 mg/mL. 16.61 mM;

c1c(ccc(c1)CC(C)C)c1nc(no1)c1ccc(c(c1)F)CN1CC(C1)C(=O)O

1-{2-Fluoro-4-[5-(4-isobutyl-phenyl)-[1,2,4]oxadiazol-3-yl]-benzyl}-azetidine-3-carboxylic acid

(-20℃)

With Ice Pack

≥ 2 years